Vertex Pharmaceuticals (Canada) Incorporated

---

Registration: 8 of 8 (2026-05-03 to present)

Details Regarding the Identified Subject Matter

Subject matters	Details	Categories
Health	Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).	Legislative Proposal, Bill or Resolution
Health	Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.	Policies or Program
Budget, Economic Development, Federal-Provincial Relations, Health	Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.	Policies or Program
Budget, Health	Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.	Policies or Program
Budget, Federal-Provincial Relations, Health	Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.	Policies or Program
Economic Development, Health, Intellectual Property	Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.	Policies or Program
Federal-Provincial Relations, Health	Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board	Regulation